Lowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) — Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ADMA Biologics (NASDAQ: ADMA) (“ADMA Biologics” or the “Company”) for potential violations of the federal securities laws. On March 24, 2026, Culper Research, an investigative research firm, published a report titled […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.